35 results about "Histologic type" patented technology

The present invention provides a drug delivery system wherein a "parachute" structure is coupled to a therapeutic compound. The "parachute" structure comprises hydrophilic branched molecules with a defined action diameter. The complex (a parachute structure coupled with a therapeutic compound) is either fixed at a cell membrane or delivered to a defined distance from the membrane within the cell. The membrane-anchoring / localizing effect of the parachute is achieved by hydrophilic structures linked with a branching unit of desired therapeutic compounds. Furthermore, the parachute structures can be connected by a spacer (e.g. beta-amino acids, gamma-amino butyric acid, or poly-amino acids) instead of directly binding to the therapeutic compound, so that the therapeutic compounds can be localized within the cells at a defined distance from the cell membrane. A spacer containing a breaking point can determine the time span, during which the drug exhibits its therapeutic activity. The hydrophilic residues can also carry signals for targeting the parachute-therapeutic complex to a defined tissue type. This can be mediated by an antibody which is specific for a tumor marker. Alternatively, a Biotin can be attached at C6 position of the sugar and then react with an Avidin-labeled tumor-specific antibody. The parachute function may also be achieved by other, more bulky hydrophilic structures such as oligosaccharides connected to the branching unit. Such sugar oligomers have specific attachment points to cell selectins, and therefore do not need additional molecular structures to target a specific tumor tissue. The use of the parachute structure gives the advantages of being able to localize a photosensitizer or chemotherapeutic drug at the site within a cell where it can destroy the tumor cell most effectively. This reduces the level of necessary systemic doses of the drugs, promotes drug excretion, and therefore considerably reduces side effects of the therapy.

Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N2O2-containing) compound or a pharmaceutically acceptable salt thereof, wherein the cancer cell has an elevated level of reactive oxygen species (ROS) and / or a decreased level of one or more of PRX1, PRX6, and OGG1, compared to a normal cell of the same tissue or tissue type. An example of a diazeniumdiolated compound is Formula (I), wherein X and Q are defined herein. Also disclosed are diazeniumdiolated compounds, pharmaceutical compositions, and methods of use including enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.

A system and method is provided for using ultrasound data backscattered from vascular tissue to estimate the transfer function of a catheter (including components attached thereto—e.g., IVUS console, transducer, etc.). Specifically, in accordance with a first embodiment of the present invention, a computing device is electrically connected to a catheter and used to acquire RF backscattered data from a vascular structure (e.g., a blood vessel, etc.). The backscattered ultrasound data is then used, together with an algorithm, to estimate the transfer function. The transfer function can then be used (at least in a preferred embodiment) to calculate response data for the vascular tissue (i.e., the tissue component of the backscattered ultrasound data). In a second embodiment of the present invention, an IVUS console is electrically connected to a catheter and a computing device and is used to acquire RF backscattered data from a vascular structure. The backscattered data is then transmitted to the computing device, where it is used to estimate the catheter's transfer function and to calculate response data for the vascular tissue. The response data and histology data are then used to characterize at least a portion of the vascular tissue (e.g., identify tissue type, etc.).

Embodiments of the present disclosure are directed to treatment planning systems for a radiotherapy apparatus. In one implementation, a treatment planning system may include a computational processor configured to apply a set of instructions to an input data set. The input data set may include a three-dimensional dose distribution for delivery by the radiotherapy apparatus to a volume to be irradiated, a three-dimensional volume image characterizing tissue types within the volume to be irradiated, and a set of apparatus parameters which characterize the radiotherapy apparatus. The set of instructions may include a computational process configured to output a treatment plan for delivery of the dose distribution by the radiotherapy apparatus, by optimising a function representing a time-dependent response of the tissue types to an applied radiation.

A system for ablation planning and treatment includes a delineation module (124) configured to distinguish tissue types in an image, the tissue types including at least a core tissue and a margin zone encapsulating the core tissue. A treatment planning module (140) is configured to apply weightings in a cost function to prioritize ablation coverage of the tissue types including the core tissue and the margin zone to determine ablation characteristics that achieve an ablation composite in accordance with user preferences. A graphical user interface (122) is rendered on a display to indicate the core tissue, the margin zone, the ablation composite and permit module user selection of one or more treatment methods.

Herein, when an electrode is used to apply an electric field in a target tissue within an anatomical volume (e.g., applying TTField to treat a tumor), the position of the electrode may be optimized by obtaining conductivity measurements in the anatomical volume and generating a 3D map of conductivity directly from the obtained conductivity or resistivity measurements without dividing the anatomical volume into tissue types. A location of the target tissue is identified within the anatomical volume, and a location for the electrode is determined based on the 3D map of conductivity and the location of the target tissue.

The invention provides molecular markers related to the prognosis of non-small cell lung cancer and applications thereof. The present invention combines the non-small cell lung cancer (NSCLC) gene chip expression data set, uses random forest method and Cox single factor regression analysis, finds the genes whose expression level is significantly related to the patient's survival period among the candidate genes, and uses Cox multifactor for these genes Regression analysis was used to model the survival analysis, and the performance of the model was evaluated by the Kaplan Meier method and the time-dependent ROC analysis method, and a lung cancer prognosis label set of 17 genes was obtained. The length of survival and the risk of recurrence are graded for individualized treatment. This molecular marker is not affected by factors such as NSCLC tissue type, disease stage, age, gender, etc. It can be used as a tool for evaluating the prognosis of NSCLC and has universal applicability to NSCLC patients.

The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof.

The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof.

A method for processing one or more histological images captured by a medical imaging device is disclosed. In this method, the histological image is received, and target regions each of which corresponds to a candidate type of tissue are identified based on a predictive model as sociating one more sample histological images with one or more sample target histological images. One or more display characteristics associated with the identified at least one target histological image is applied to the histological image.

The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.

The present invention relates to a composition comprising an isolated CD4+ Treg cell population, wherein the Treg cells have signatures for i) identifying that the T-cells are CD4+ regulatory Tcells, ii) identifying that the Treg cells are tissue type tropic, i.e they can migrate to the diseased tissue, iii) optionally identifying that the Treg cells are tropic with respect to the diseased tissue, i.e. they are homing cells, iv) identifying that the Treg cells are emigrant cells, i.e. they originate from the target tissue, and v) optionally identifying that the Treg cells are retained in the target tissue and optionally one or more X-signatures and / or one or more Y-signatures and one ore more Z-signatures.

A monoclonal antibody, 3E10, and active fragments thereof that selectively are transported in vivo to the nucleus of mammalian cells without cytotoxic effect are provided. The antibody and other molecules that bind to a variant of myosin IIb heavy chain found in the nucleus of skeletal muscle cells are useful as a non-viral delivery vector to target skeletal muscle in vivo. By contrast, in vitro the monoclonal antibody penetrates and is transported to the nucleus of multiple cell lines derived from different tissue types and can be used in screening tests to identify molecules that modulate growth of cells, such as cancer cells. Non-cytotoxic vectors for delivering a drug, polynucleotide or polypeptide selectively to skeletal muscle cells are also provided.